Navigation Links
Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics' Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
Date:12/14/2011

BANNOCKBURN, Ill., Dec. 14, 2011 /PRNewswire/ -- Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today that it has obtained approval for an Orphan Drug Designation (ODD) for their product PHOTOFRIN® (porfimer sodium) as adjuvant therapy to surgery in the treatment of malignant pleural mesothelioma.

Malignant pleural mesothelioma is a form of cancer affecting the lining of the lungs. It is a rare, highly aggressive and devastating cancer with a poor prognosis. The incidence of malignant pleural mesothelioma has been linked to previous asbestos exposure and has grown from almost zero to approximately 3,000 new cases each year in the United States.(1)

"We are pleased to have obtained from the FDA the Orphan Drug Designation for PHOTOFRIN® for treatment in malignant mesothelioma," said Guillermo Herrera, Executive Chairman of Pinnacle Biologics. "Presently, the treatments for mesothelioma are palliative at best, and the outcome in patients with malignant pleural mesothelioma is very poor.  Pinnacle is evaluating current clinical data so as to formulate a plan to bring this important treatment option to patients with malignant pleural mesothelioma in the near future."

According to Patrick Ross, M.D., Ph.D., Professor Clinical Thoracic Surgery, "I am pleased with the FDA decision granting PHOTOFRIN® orphan drug designation for mesothelioma. Photodynamic Therapy (PDT) with PHOTOFRIN® has shown tremendous value as a treatment modality in several forms of cancer providing doctors and health care providers with innovative options to treat unmet medical needs such as mesothelioma and other indications presently under investigation." 

About Photodynamic therapy (PDT) and PHOTOFRIN®

Photodynamic therapy with
'/>"/>

SOURCE Pinnacle Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Wellington Hospital, New Zealand Becomes First in Southern Hemisphere to Offer Patients Fast and Precise TrueBeam Treatments
2. Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML)
3. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients With Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
4. Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
5. The European Commission Grants Marketing Authorization for DIFICLIR™ (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections
6. Weight Loss and Effects on Diabetes with Qnexa Treatment Results Presented at the World Diabetes Congress
7. First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease
8. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
9. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
10. Philips Answers the Call for Worldwide Access to Advanced Imaging Systems for Diagnosis and Treatment
11. SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... LOS ANGELES, May 1, 2015  CytRx Corporation ... in oncology, today reported financial results for the ... an overview of recent accomplishments and upcoming milestones ... achieved several milestones in the early months of ... its clinical trial of aldoxorubicin in patients with ...
(Date:5/1/2015)... MARLBOROUGH, Mass. , May 1, 2015  Boston ... overview of its continued business momentum and long-term growth ... in New York City . President ... outline the unique opportunities the company has to bring ... into fast growing markets and deliver shareholder value. ...
(Date:5/1/2015)...  Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ... the results of the Phase 3 Rocket 1 trail ... failing to meet its end points, compelling data from ... future studies. An analyst report on AERI ... review, analyst summary, valuation, and recommendation can be viewed ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved ... from Exenatide Taken Twice a Day, SAN FRANCISCO, ... Eli Lilly and Company (NYSE: LLY ), and ... a 52-week open-label clinical,study that showed the durable efficacy ...
... VIEW, Calif., June 9 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R),alprazolam) ... not meet its two,primary endpoints, which were the ... panic attack and the effect of AZ-002 on ...
Cached Medicine Technology:After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
(Date:5/3/2015)... 03, 2015 SpineFrontier, a Less Exposure ... FDA to produce and market their new sacroiliac joint ... used in outpatient settings and is compatible with both ... approach has been extensively researched and refined by SpineFrontier, ... use this approach in conjunction with a sacroiliac joint ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... today, Saturday, May 2nd at the MGM Grand Garden Arena ... to secure tickets for both the actual fight and various ... wanted for more than five years was finally been agreed ... inside the ring to fight Manny “Pac-Man” Pacquiao in what ...
(Date:5/2/2015)... May 02, 2015 “ ActOn ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... get connected with organizations to make a difference. , In ... very few things that aren’t about money, which is why ...
(Date:5/2/2015)... NY (PRWEB) May 02, 2015 It’s ... a deadly natural disaster strikes anywhere on this planet, ... leverage human sympathy and compassion for their own personal ... States Computer Emergency Readiness Team) issued an alert ... “of potential email scams citing the earthquake in Nepal. ...
Breaking Medicine News(10 mins):Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4
... When you check into a hospital, the odds are one ... of antibiotic-resistant bacteria as a result of your stay. That ... todays hospitals despite the best efforts of the medical profession. ... deaths per year., Now, a sophisticated new mathematical model has ...
... for,Plastination commends ABC,s 20/20 for its investigation on ... exhibitions. The program served to,inform and educate the ... of bodies used in anatomical exhibitions in particular., ... clarify two vague,statements made by anatomist, Dr. Gunther ...
... survival rates to younger cases , , FRIDAY, Feb. 15 ... transplantation and have good outcomes, and age should not ... a new study says. , Researchers at the University ... of 48 UCLA patients between the ages of 65 ...
... Canadian scientists are finding that out of sight, out of ... the chemicals in our waters. Substances that we use everyday ... they can impact aquatic life and possibly ourselves. , ... of the 30,000 or so chemicals used commercially in the ...
... Premier Exhibitions Inc.,(Nasdaq: PRXI ) today posted ... to an expected 20/20 broadcast that is purported ... to its controversial and,highly successful bodies exhibitions., ... TV,s 20/20 has,chosen to air a segment that ...
... 15 IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced ... by the Company of an additional four million,shares of ... will be made in the open market or in ... shares remaining as of,December 31, 2007, under a previous ...
Cached Medicine News:Health News:Math model identifies key to controlling epidemic 2Health News:Math model identifies key to controlling epidemic 3Health News:Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program 2Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:New findings on emerging contaminants 2Health News:New findings on emerging contaminants 3Health News:New findings on emerging contaminants 4Health News:New findings on emerging contaminants 5Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 2Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 3
Straight shafts with 6 mm tying platform and crisscross serrated tips. Round knurled handle with polished finish. Overall length 4.5 inches....
Curved shafts and tips with 5.5 mm tying platform. 0.3 mm gap at platform heel. True round knurled handle in closed position with polished finish. Overall length 4.3 inches....
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches....
5 mm tying platform. Round knurled handle with dull finish. Straight shafts. Overall length 3.9 inches....
Medicine Products: